Regulatory Pathways for Generic Antiviral Drugs: ANDA Requirements in the USA Compared With BRICS
International Journal of Life Science and Pharma Research · 13.11.2026 · 64-75
DOI: 10.22376/ijlpr.v16i3.2059 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Life Science and Pharma Research, online erschienen am 13.11.2026. Verfasst von Shirisha Mangilipally und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Generic antiviral medicines widened access to treatment for chronic and epidemic viral infections once patents on branded products expired. Approval requirements for generic medicines differed between countries, and earlier comparisons either described frameworks that were later replaced or gave little attention to antiviral-specific bioequivalence expectations. This study compares the abbreviated new drug application pathway of the United States Food and Drug Administration with generic drug registration in Brazil, Russia, India, China and South Africa, and it illustrates product-specific bioequivalence expectations for two antivirals, acyclovir topical cream and oseltamivir phosphate capsules. The novelty of the study lies in combining country-level procedures with antiviral case studies and in correcting superseded descriptions found in earlier compilations. The work is a descriptive comparative review. Regulatory instruments, regulator publications, product-specific guidances and published comparative studies are compiled, and six parameters (regulator, legal basis, dossier format and language, review structure, bioequivalence approach and indicative review duration) are tabulated for each country. Time-sensitive items are checked against notices current in November 2026. No statistical analysis is applicable to this descriptive study. All six jurisdictions use a dossier organised on the Common Technical Document and require proof of bioequivalence to a reference product, but they differ in legal basis, language, review structure, reliance on assessments by other regulators, patent-linkage mechanisms and reported review duration. Earlier descriptions are superseded in several respects: the Chinese and South African regulators have been renamed, Russia registers medicines under Eurasian Economic Union rules, the Brazilian generic requirements are consolidated in a 2022 resolution, and the Indian rules of 2019 replaced Schedule Y. The acyclovir case shows that a topical product can be approved through formulation sameness with in vitro release testing or through a clinical endpoint study, whereas the oseltamivir case shows that an oral capsule can be approved through a biowaiver based on the Biopharmaceutics Classification System or through fasting and fed crossover studies. Convergence on the Common Technical Document and on bioequivalence principles lowers the barrier to multi-country filing, but national legal instruments, language, timelines and product-specific expectations still require a jurisdiction-specific strategy.
Zitieren
APA
Mangilipally, S., Lingala, D., Dusa, J., S, A. T., Bogi, N., Aeluka, R., & D, P. (2026). Regulatory Pathways for Generic Antiviral Drugs: ANDA Requirements in the USA Compared With BRICS. International Journal of Life Science and Pharma Research, 64-75. https://doi.org/10.22376/ijlpr.v16i3.2059
Vancouver
Mangilipally S, Lingala D, Dusa J, S AT, Bogi N, Aeluka R, et al. Regulatory Pathways for Generic Antiviral Drugs: ANDA Requirements in the USA Compared With BRICS. International Journal of Life Science and Pharma Research. 2026:64-75. doi:10.22376/ijlpr.v16i3.2059
BibTeX
@article{Mangilipally2026,
author = {Mangilipally, Shirisha and Lingala, Deepthi and Dusa, Jayasri and S, Apoorva Teja and Bogi, Nikitha and Aeluka, Reshma and D, Prasanthi},
title = {Regulatory Pathways for Generic Antiviral Drugs: ANDA Requirements in the USA Compared With BRICS},
journal = {International Journal of Life Science and Pharma Research},
year = {2026},
pages = {64--75},
doi = {10.22376/ijlpr.v16i3.2059}
}
EUVIMED